RNA Outsourcing Videos

  1. How "Successful" Are Our mRNA-LNP Outsourcing Partnerships Today? 2/10/2025

    In this snippet, panelist Alex Aust (with the help of several live attendee commenters) tackles a particularly tricky question: Are our outsourcing partnerships producing high quality products today, and what are the most common root causes of batch failures?

  2. How Can Sponsors & CDMOs Collaborate On RNA Analytical/Process Development? 8/22/2024

    Having worked on both the innovator and CDMO sides of the industry, Advancing RNA LIVE panelist Khaled Yamout outlines where he sees the greatest weaknesses in these critical sponsor-CDMO partnerships and offers guidance.

  3. mRNA Capabilities 3/4/2025

    Discover how our advanced capabilities in Hopkinton, MA, are overcoming the challenges of large-scale RNA therapeutic manufacturing, enabling the efficient production of complex srRNA and mRNA therapies.

  4. Recipharm Advanced Bio Capabilities Update September 2026: mRNA 10/8/2026

    RNA therapeutics are reshaping disease treatment, but success requires coordinated expertise in plasmid production, RNA synthesis, formulation, analytics, and manufacturing.

  5. Validation Of mRNA Concentration Determination 8/20/2023

    mRNA-based therapeutics require comprehensive analytical testing to meet regulatory requirements. Optimize processes and ensure fast and reliable results as you bring your product to market.

  6. How Outsourcing mRNA Development Has Evolved Since COVID 2/10/2025

    Advancing RNA panelists Alex Aust, Qian Ruan, and Andy Geal share their thoughts on the ways in which outsourcing firms are approaching mRNA development today, as well as why outsourcing — as opposed to building a GMP facility — remains critical for (x)RNA biotechs today.

  7. How Are The Costs Of mRNA-LNP Manufacturing Evolving? 2/10/2025

    Achieving cost-effective manufacturing while maintaining high quality standards today is one of the biggest challenges facing companies outsourcing mRNA/RNA development. In turn, panelists Qian Ruan, Andy Geall, and Alex Aust reflect on how and where they’ve seen the costs of mRNA-LNP manufacturing evolving/fluctuating in recent years.

  8. Addressing mRNA's Scalability And Supply Challenges 3/14/2022

    Tune in as Roberta Duncan, VP of the mRNA program at Seqirus; Duke Human Vaccine Institute Associate Director of Upstream and Downstream Process Development Jason Dickens, Ph.D.; and Jin Zhou, Executive Director of Process Development for mRNA and Protein Biologics at Ultragenyx share supply chain and manufacturing capacity constraints in the face of the urgency to address COVID-19. This is an excerpt from the Bioprocess Online Live event - mRNA Manufacturing: Bright Future, Big Challenges.

  9. New Promises, New Pressures, No Problem - Service Care Packages 8/19/2026

    Tighter production schedules leave little room for equipment disruption. Get support that can strengthen maintenance strategies, reduce operational risk, and help internal teams sustain performance.

  10. RNA Whole Transcriptome Sequencing From Challenging Matrices: Insights From Tissue 10/20/2026

    RNA extraction from skin, gut, and tumor biopsies demands a systematic approach, from sample preservation through porcine method development to human validation, with direct consequences for sequencing performance.